نتائج البحث - "A. M. Mamedyarov"

العلاقة: https://vsp.spr-journal.ru/jour/article/view/3267/1312Test; Hingorani M, Hanson I, van Heyningen V. Aniridia. Eur J Hum Genet. 2012;20(10):1011–1017. doi: https://doi.org/10.1038/ejhg.2012.100Test; Воскресенская А.А., Поздеева Н.А., Васильева Т.А. и др. Клинические особенности врожденной аниридии в детском возрасте // Российская педиатрическая офтальмология. — 2016. — Т. 11. — № 3. — С. 121–129. — doi: https://doi.org/10.18821/1993-1859-2016-11-3-121-129Test; Tibrewal S, Ratna R, Gour A, et al. Clinical and molecular aspects of congenital aniridia — A review of current concepts. Indian J Ophthalmol. 2022;70(7):2280–2292. doi: https://doi.org/10.4103/ijo.IJO_2255_21Test; Bamiou DE, Free SL, Sisodiya SM, et al. Auditory interhemispheric transfer deficits, hearing difficulties, and brain magnetic resonance imaging abnormalities in children with congenital aniridia due to PAX6 mutations. Arch Pediatr Adolesc Med. 2007;161(5):463–469. doi: https://doi.org/10.1001/archpedi.161.5.463Test; Hu P, Meng L, Ma D, et al. A novel 11p13 microdeletion encompassing PAX6 in a Chinese Han family with aniridia, ptosis and mental retardation. Mol Cytogenet. 2015;8(1):3. doi: https://doi.org/10.1186/s13039-015-0110-2Test; Hanish AE, Butman JA, Thomas F, et al. Pineal hypoplasia, reduced melatonin and sleep disturbance in patients with PAX6 haplo-insufficiency. J Sleep Res. 2016;25(1):16–22. doi: https://doi.org/10.1111/jsr.12345Test; Lee HJ, Colby KA. A review of the clinical and genetic aspects of aniridia. Semin Ophthalmol. 2013;28(5-6):306–312. doi: https://doi.org/10.3109/08820538.2013.825293Test; Касман-Келнер Б., Вейстенц А., Зейц Б. Медицинское сопровождение врожденной аниридии и аниридийного синдрома (РАХ6-синдрома) // Практическая медицина. — 2015. — № 1-2. — C. 34–61.; Васильева Т.А., Поздеева Н.А., Воскресенская А.А. и др. Генетические аспекты врожденной аниридии // Практическая медицина. — 2015. — № 2-1 — С. 26–33.; Васильева Т.А., Воскресенская А.А., Поздеева Н.А. и др. Характеристика гена РАХ6 и роль его мутаций в развитии наследственной патологии органа зрения // Генетика. — 2018. — Т. 54. — № 9. — С. 979–987. — doi: https://doi.org/10.1134/S0016675818090151Test; Wawrocka A, Krawczynski MR. The genetics of aniridia — simple things become complicated. J Appl Genet. 2018;59(2):151–159. doi: https://doi.org/10.1007/s13353-017-0426-1Test; Васильева Т.А., Воскресенская А.А., Хлебникова О.В. и др. Дифференциальная диагностика наследственных форм врожденной аниридии с позиций современной генетики // Вестник РАМН. — 2017. — Т. 72. — № 4. — С. 233–241. — doi: https://doi.org/10.15690/vramn834Test; Ansari M, Rainger J, Hanson IM, et al. Genetic Analysis of ‘PAX6-Negative’ Individuals with Aniridia or Gillespie Syndrome. PLoS One. 2016;11(4):e0153757. doi: https://doi.org/10.1371/journal.pone.0153757Test; Kim KC, Lee DK, Go HS, et al. Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring. Mol Neurobiol. 2014;49(1):512–528. doi: https://doi.org/10.1007/s12035-013-8535-2Test; Эль-Ансари А. ГАМК, дефициты нейротрансмиттера глутамата при аутизме и их нейтрализация как новая гипотеза эффективной стратегии лечения // Аутизм и нарушения развития. — 2020. — Т. 18. — № 3. — C. 46–63. — doi: https://doi.org/10.17759/autdd.2020180306Test; Glaser T, Jepeal L, Edwards JG, et al. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nature Genet. 1994;7(4):463–471. doi: https://doi.org/10.1038/ng0894-463Test; Tyas DA, Pearson H, Rashbass P, Price DJ. Pax6 regulates cell adhesion during cortical development. Cereb Cortex. 2003;13(6): 612–619. doi: https://doi.org/10.1093/cercor/13.6.612Test; Schmidt-Sidor B, Szymańska K, Williamson K, et al. Malformations of the brain in two fetuses with a compound heterozygosity for two PAX6 mutations. Folia Neuropathol. 2009;47(4):372–382.; Fischbach BV, Trout KL, Lewis J, et al. WAGR syndrome: a clinical review of 54 cases. Pediatrics. 2005;116(4):984–988. doi: https://doi.org/10.1542/peds.2004-0467Test; Yogarajah M, Matarin M, Vollmar C, et al. M. PAX6, brain structure and function in human adults: advanced MRI in aniridia. Ann Clin Transl Neurol. 2016;3(5):314–330. doi: https://doi.org/10.1002/acn3.297Test; Käsmann-Kellner B, Berthold S. Kongenitale Aniridie oder PAX6-Syndrom. Ophthalmologe. 2014;111(12):1144. doi: https://doi.org/10.1007/s00347-014-3058-4Test; Malandrini A, Mari F, Palmeri S, et al. PAX6 mutation in a family with aniridia, congenital ptosis, and mental retardation. Clin Genet. 2001;60(2):151–154. doi:https://doi.org/10.1034/j.1399-0004.2001.600210.xTest; Катаргина Л.А., Мазанова Е.В., Тарасенков А.О. Клинико-функциональные особенности врожденной аниридии и сочетанной с ней патологии // Российская педиатрическая офтальмология. — 2015. — Т. 10. — № 3. — С. 21–23.; Landsend ECS, Lagali N, Utheim TP. Congenital aniridia — A comprehensive review of clinical features and therapeutic approaches. Surv Ophthalmol. 2021;66(6):1031–1050. doi: https://doi.org/10.1016/j.survophthal.2021.02.011Test; Robinson DO, Howarth RJ, Williamson KA, et al. Genetic analysis of chromosome 11p13 and the PAX6 gene in a series of 125 cases referred with aniridia. Am J Med Genet A. 2008;146A(5):558–569. doi: https://doi.org/10.1002/ajmg.a.32209Test; Bobilev AM, Hudgens-Haney ME, Hamm JP, et al. Early and late auditory information processing show opposing deviations in aniridia. Brain Res. 2019;1720:146307. doi: https://doi.org/10.1016/j.brainres.2019.146307Test; Bamiou DE, Campbell NG, Musiek FE, et al. Auditory and verbal working memory deficits in a child with congenital aniridia due to a PAX6 mutation. Int J Audiol. 2007;46(4):196–202. doi: https://doi.org/10.1080/14992020601175952Test; Кельмансон И.А. Хронопатологические аспекты расстройств сна и когнитивных функций у детей с нарушениями зрения // Российский вестник перинатологии и педиатрии. — 2015. — Т. 60. — № 5. — С. 42–50.; Berntsson SG, Kristoffersson A, Daniilidou M, et al. Aniridia with PAX6 mutations and narcolepsy. J Sleep Res. 2020;29(6):e12982. doi: https://doi.org/10.1111/jsr.12982Test; Moosajee M, Hingorani M, Moore AT. PAX6-Related Aniridia. 2003 May 20 [Updated 2018 Oct 18]. In: GeneReviews® [Internet]. Adam MP, Everman DB, Mirzaa GM, et al., eds. Seattle (WA): University of Washington, Seattle; 1993–2022.; Guo R, Zhang X, Liu A, et al. Novel clinical presentation and PAX6 mutation in families with congenital aniridia. Front Med (Lausanne). 2022;9:1042588. doi: https://doi.org/10.3389/fmed.2022.1042588Test; Дамулин И.В., Тардов М.В. Клинико-патогенетические особенности мозжечковой атаксии // Трудный пациент. — 2020. — Т. 18. — № 10. — С. 17–23. — doi: https://doi.org/10.24411/2074-1995-2020-10067Test; Grant MK, Bobilev AM, Pierce JE, et al. Structural brain abnormalities in 12 persons with aniridia. F1000Res. 2017;6:255. doi: https://doi.org/10.12688/f1000research.11063.2Test; Solomon BD, Pineda-Alvarez DE, Balog JZ, et al. Compound heterozygosity for mutations in PAX6 in a patient with complex brain anomaly, neonatal diabetes mellitus, and microophthalmia. Am J Med Genet. 2009;149A(11):2543–2546. doi: https://doi.org/10.1002/ajmg.a.33081Test; Ugalahi MO, Ibukun FA, Olusanya BA, Baiyeroju AM. Congenital aniridia: Clinical profile of children seen at the University College Hospital, Ibadan, South-West Nigeria. Ther Adv Ophthalmol. 2021;13:25158414211019513. doi: https://doi.org/10.1177/25158414211019513Test; Генинг Г.Н. Влияние врожденной аниридии на палитру психических состояний пациентов с аниридией и родителей детей с аниридией // Семья и дети в современном мире: сборник материалов конференции. — СПб.: Изд-во РГПУ им. А.И. Герцена; 2019. — Т. 5. — С. 135.; Nishizawa H, Motobayashi M, Akahane M, et al. Neuro-psychological and neurophysiological features of WAGR syndrome: Detailed comprehensive evaluation of a patient with severe intellectual disability and autism spectrum disorder. Brain Dev. 2022;44(3):229–233. doi: https://doi.org/10.1016/j.braindev.2021.11.06Test; Han JC, Liu QR, Jones M, et al. Brain-Derived Neurotrophic Factor and Obesity in the WAGR Syndrome. N Engl J Med. 2008;359(9): 918–927. doi: https://doi.org/10.1056/NEJMoa0801119Test; Shinawi M, Sahoo T, Maranda B, et al. 11p14.1 microdeletions associated with ADHD, autism, developmental delay, and obesity. Am J Med Genet A. 2011;155:1272–1280. doi: https://doi.org/10.1002/ajmg.a.33878Test; Yamamoto T, Togawa M, Shimada S, et al. Narrowing of the responsible region for severe developmental delay and autistic behaviors in WAGR syndrome down to 1.6 Mb including PAX6, WT1, and PRRG4. Am J Med Genet A. 2014;164A(3):634–638. doi: https://doi.org/10.1002/ajmg.a.36325Test; Duffy KA, Trout KL, Gunckle JM, et al. Results From the WAGR Syndrome Patient Registry: Characterization of WAGR Spectrum and Recommendations for Care Management. Front Pediatr. 2021; 9:733018. doi: https://doi.org/0.3389/fped.2021.733018Test; https://vsp.spr-journal.ru/jour/article/view/3267Test

الإتاحة: https://doi.org/10.15690/vsp.v22i4.2611Test
https://doi.org/10.1038/ejhg.2012.100Test
https://doi.org/10.18821/1993-1859-2016-11-3-121-129Test
https://doi.org/10.4103/ijo.IJO_2255_21Test
https://doi.org/10.1001/archpedi.161.5.463Test
https://doi.org/10.1186/s13039-015-0110-2Test
https://doi.org/10.1111/jsr.12345Test
https://doi.org/10.3109/08820538.2013.825293Test
https://doi.org/10.1134/S0016675818090151Test
https://doi.org/10.1007/s13353-017-0426-1Test

View record in BASE

7

دورية أكاديمية

The Concept of «Key Muscles» and the Early Onset of Botulinum Therapy in Spastic Forms of Cerebral Palsy ; Концепция «ключевых мышц» и раннее начало ботулинотерапии при спастических формах детского церебрального паралича

المؤلفون: Olga A. Klochkova, Alexey L. Kurenkov, Leyla S. Namazova-Baranova, Ayaz M. Mamedyarov, Khadizhat M. Karimova, Margarita A. Kuznetsova, О. А. Клочкова, А. Л. Клочкова, Л. С. Намазова-Баранова, А. М. Мамедьяров, Х. М. Каримова, М. А. Кузнецова

المصدر: Current Pediatrics; Том 16, № 1 (2017); 39-48 ; Вопросы современной педиатрии; Том 16, № 1 (2017); 39-48 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: концепция «ключевых мышц», cerebral palsy, spasticity, botulinum therapy, botulinum toxin type A, concept of «key muscles», детский церебральный паралич, спастичность, ботулинотерапия, ботулинический токсин типа А

وصف الملف: application/pdf

العلاقة: https://vsp.spr-journal.ru/jour/article/view/1729/680Test; Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet. 2004;363(9421):1619–1631. doi:10.1016/S0140-6736(04)16207-7.; Семенова К.А. Восстановительное лечение детей с перинатальным поражением нервной системы и детским церебральным параличом. — М.: Закон и порядок; 2007. — 616 с. [Semenova KA. Vosstanovitel’noe lechenie detei s perinatal’nym porazheniem nervnoi sistemy i detskim tserebral’nym paralichom. Moscow: Zakon i poryadok; 2007. 616 p. (In Russ).]; Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47(8):571–576. doi:10.1017/s001216220 500112x.; SCPE. Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol. 2002;44(9):633–640. doi:10.1111/j.1469-8749.2002.tb00848.x.; Wichers MJ, Odding E, Stam HJ, van Nieuwenhuizen O. Clinical presentation, associated disorders and aetiological moments in cerebral palsy: a Dutch population-based study. Disabil Rehabil. 2005;27(10):583–589. doi:10.1080/09638280400018445.; Leonard J, Graham HK. Treatment of motor disorders in cerebral palsy with botulinum neurotoxin. In: Jankovic J, editor. Botulinum toxin: Therapeutic clinical practice and science. Philadelphia:Saunders Elsevier; 2009. p. 172–191. doi:10.1016/b978-1-4160-4928-9.00014-7.; Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1): 45–66. doi:10.1016/j.ejpn.2009.09.005.; Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910. doi:10.1111/dmcn.12246.; Hagglund G, Wagner P. Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet Disord. 2008;9:150. doi:10.1186/1471-2474-9-150.; Hagglund G, Andersson S, Duppe H, et al. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme. J Bone Joint Surg Br. 2005;87:95–101. doi:10.1302/0301-620X.87B1.15146.; Pascual-Pascual S, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol. 2009;13(6):511–515. doi:10.1016/j.ejpn.2008.10.006.; Druschel C, Althuizes HC, Funk JF, Placzek R. Off label use of botulinum toxin in children under two years of age: а systematic review. Toxins (Basel). 2013;5(1):60–72. doi:10.3390/toxins5010060.; Tilton AH. Evidence-based review of safety and efficacy in cerebral palsy. Toxicon. 2015;107(Pt A):105–108. doi:10.1016/j.toxicon.2015.09.020.; Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–193. doi:10.1146/annurev.pharmtox.44.101802.121554.; Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131–133. doi:10.1016/s0733-8635(03)00019-6.; Koman LA, Mooney JF, Smith B, et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993;13(4):489–495. doi:10.1097/01241398-199307000-00013.; Pascual-Pascual SI, Herrera-Galante A, Poo P, et al. [Guidelines for the treatment of child spasticity using botulinum toxin. (In Spanish).] Rev Neurol. 2007;44(5):303–309.; Arner M, Himmelmann K, Ponten E, et al. [Upper extremity botulinum toxin treatment in cerebral palsy. Treatment guidelines the first step towards national cooperation. (In Swedish).] Lakartidningen. 2008;105(43):3009–3013.; National Collaborating Centre for Women’s and Children’s Health (UK). Spasticity in children and young people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and their early musculoskeletal complications. London: RCOG Press; 2012. p. 293.; Delgado M, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–343. doi:10.1212/WNL.0b013e3181cbcd2f.; Placzek R. [Botulinum toxin A in children with infantile cerebral palsy: indications and treatment concepts. (In German).] Orthopade. 2010;39(1):23–30. doi:10.1007/s00132-009-1534-3.; Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop. 1998;18(3): 304–11. doi:10.1097/01241398-199805000-00006.; Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67–79. doi:10.1016/S0966-6362(99)00054-5.; Molenaers G, Fagard K, Van Campenhout A, Desloovere K. Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop. 2013;7(5):383–387. doi:10.1007/s11832-013-0511-x.; Rathinam C, Bateman A, Peirson J, Skinner J. Observational gait assessment tools in paediatrics — a systematic review. Gait Posture. 2014;40(2):279–285. doi:10.1016/j.gaitpost.2014.04.187.; Metaxiotis D, Siebel A, Doederlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop Relat Res. 2002;(394):177–185. doi:10.1097/00003086-200201000-00021.; Goldberg MJ. Botulinum toxin type a improved ankle function in children with cerebral palsy and dynamic equinus foot deformity. J Bone Joint Surg Am. 2000;82(6):874. doi:10.2106/00004623-200006000-00016.; Love SC, Valentine JP, Blair EM, et al. The effect of botulinum toxin type a on the functional ability of the child with spastic hemiplegia a randomized controlled trial. Eur J Neurol. 2001;8 Suppl 5: 50–58. doi:10.1046/j.1468-1331.2001.00038.x.; Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type a injections in the spastic upper extremity of children with hemiplegia: Child characteristics that predict a positive outcome. Eur J Neurol. 2001;8 Suppl 5:145–149. doi:10.1046/j.1468-1331.2001.00047.x.; Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of «highdose » versus «low-dose» treatment. Neuropediatrics. 1999;30(3): 120–124. doi:10.1055/s-2007-973475.; Fazzi E, Maraucci I, Torrielli S, et al. Factors predicting the efficacy of botulinum toxin-a treatment of the lower limb in children with cerebral palsy. J Child Neurol. 2005;20(8):661–666. doi:10.1177/08830738050200080501.; Gough M, Fairhurst C, Shortland AP. Botulinum toxin and cerebral palsy: time for reflection? Dev Med Child Neurol. 2005;47(10): 709–712. doi:10.1017/S0012162205001453.; Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994;36(5):386–396. doi:10.1111/j.1469-8749.1994. tb11864.x.; Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10:215–225. doi:10.1016/j.ejpn.2006.08.006.; Molenaers G, Schorkhuber V, Fagard K, et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol. 2009;13(5):421–429. doi:10.1016/j.ejpn.2008.07.008.; Naumann M, Albanese A, Heinen F, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006; 13 Suppl 4:35–40. doi:10.1111/j.1468-1331.2006.01652.x.; Willis AW, Crowner B, Brunstrom JE, et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol. 2007;49(11):818–822. doi:10.1111/j.1469-8749.2007.00818.x.; Crowner BE, Brunstrom JE, Racette BA. Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol. 2007;30(5):310–313. doi:10.1097/WNF.0b013e31804b1a0d.; Naidu K, Smith K, Sheedy M, et al. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol. 2010;52(2):139–144. doi:10.1111/j.1469-8749.2009.03583.x.; Клочкова О.А., Куренков А.Л., Намазова-Баранова Л.С., и др. Общее моторное развитие и формирование функции рук у пациентов со спастическими формами детского церебрального паралича на фоне ботулинотерапии и комплексной реабилитации // Вестник Российской академии наук. — 2013. — Т. 68. —№ 11 — С. 38–48. [Klochkova OA, Kurenkov AL, Namazova-Baranova LS, et al. Development of motor functions and manual abilities in pediatric patients with spastic cerebral palsy after botulinum toxin treatment and complex rehabilitation. Annals of the Russian academy of medical sciences. 2013;68(11):38–48. (In Russ).] doi:10.15690/vramn.v68i11.842 (In Russ).]; Куренков А.Л., Клочкова О.А. Ботулинотерапия детского церебрального паралича. В кн.: Азбука ботулинотерапии / Под ред. С.Л. Тимербаевой. — М.: Практическая медицина; 2014. — С. 148—171. [Kurenkov AL, Klochkova OA. Botulinoterapiya detskogo tserebral’nogo paralicha. In: Timerbaeva S.L., editor. Azbuka botulinoterapii. Moscow: Prakticheskaya meditsina; 2014. p. 148–171. (In Russ).]; Калинина Л.В., Сологубов Е.Г., Лузинович В.М., Дутикова Е.М. Ботокс в комплексном лечении детского церебрального паралича // Журнал невропатологии и психиатрии им. С.С. Корсакова. — 2000. — Т. 100. — № 12 — С. 60–63. [Kalinina LV, Sologubov EG, Luzinovich VM, Dutikova EM. Botoks v kompleksnom lechenii detsko go tserebral’nogo paralicha. Zh Nevrol Psikhiatr Im S S Korsakova. 2000;100(12):60–63. (In Russ).]; Калинина Л.В., Дутикова Е.М. Детский церебральный паралич. В кн.: Применение Ботокса (токсина ботулизма типа А) в клинической практике: руководство для врачей / Под ред. O.P. Орловой, H.H. Яхно. — М.: Каталог; 2001. — С. 86–107. [Kalinina LV, Dutikova EM. Detskii tserebral’nyi paralich. In: Orlova O.P., Yakhno N.N., editors. Primenenie Botoksa (toksina botulizma tipa A) v klinicheskoi praktike: rukovodstvo dlya vrachei. Moscow: Katalog; 2001. p. 86–107. (In Russ).]; Сальков В.Н., Лильин Е.Т., Степанченко О.В., и др. Ботокс при трицепс-синдроме у детей с детским церебральным параличом //Журнал неврологии и психиатрии им. С.С. Корсакова. — 2002. — Т. 102. — № 5 — С. 24–25. [Sal’kov VN, Lil’in ET, Stepanchenko OV, et al. Botoks pri tritseps-sindrome u detei s detskim tserebral’nym paralichom. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(5): 24–25. (In Russ).]; Куренков А.Л., Батышева Т.Т., Никитин С.С., и др. Лечение спастичности у детей с церебральными параличами. Методические рекомендации № 15 Департамента здравоохранения города Москвы. — М.; 2011. — C. 3–5. [Kurenkov AL, Batysheva TT, Nikitin SS, et al. Lechenie spastichnosti u detei s tserebral’nymi paralichami. Metodicheskie rekomendatsii № 15 Departamenta zdravookhraneniya goroda Moskvy. Moscow; 2011. p. 3–5. (In Russ).]; Куренков А.Л., Батышева Т.Т., Виноградов А.В., Зюзяева Е.К. Спастичность при детском церебральном параличе: диагностика и стратегии лечения // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2012. — Т. 112. — № 7–2 — С. 24–28. [Kurenkov AL, Batysheva TT, Vinogradov AV, Ziuziaeva EK. Spasticity in children cerebral palsy: diagnosis and treatment strategies. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(7–2):24–28. (In Russ).]; Клочкова О.А., Куренков А.Л., Каримова Х.М., и др. Мно гоуровневые инъекции ботулинического токсина типа А (Або ботулотоксина) при лечении спастических форм детского церебрального паралича: ретроспективное исследование опыта 8 российских центров // Педиатрическая фармакология. — 2016. — Т. 13. — № 3 — С. 259–269. [Klochkova OA, Kurenkov AL, Karimova KhM, et al. Multilevel botulinum toxin A (abobotulinum toxin A) injections in spastic forms of cerebral palsy: retrospective analysis of 8 Russian centers experience. Pediatric pharmacology. 2016;13(3):259–269. (In Russ).] doi:10.15690/pf.v13i3.1576.; Куренков А.Л., Клочкова О.А., Бурсагова Б.И., и др. Применение препарата ботулинического токсина типа А (Ботокс) в лечении детского церебрального паралича // Нервно-мышечные болезни. — 2014. — № 3 — С. 28–41. [Kurenkov AL, Klochkova OA, Bursagova BI, et al. Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy. Nervno-myshechnye bolezni. 2014;(3):28–41. (In Russ).]; Куренков А.Л., Клочкова О.А., Змановская В.А., и др. Первый Российский консенсус по применению многоуровневых инъекций Abobotulinumtoxin A при лечении спастических форм детского церебрального паралича // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2016. — Т. 116. — № 11 — С. 121–130. [Kurenkov AL, Klochkova OA, Zmanovskaya VA, et al. Pervyi Rossiiskii konsensus po primeneniyu mnogourovnevykh in»ektsii Abobotulinumtoxin A pri lechenii spasticheskikh form detskogo tserebral’nogo paralicha. Zh Nevrol Psikhiatr Im S S Korsa kova. 2016;116(11):121–130. (In Russ).]; Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:9–37. doi:10.1111/j.1468-1331.2010.03126.x.; Placzek R, Siebold D, Funk JF. Development of treatment concepts for the use of botulinum toxin A in children with cerebral palsy. Toxins (Basel). 2010;2(9):2258–2271. 10.3390/toxins2092258.; Placzek R, Salem KH, Meiss LA, et al. The key-muscle concept: a long-term low-dose injection strategy for botulinum toxin A treatment in cerebral palsy. Acta Orthop Belg. 2012;78(1):111–116.; Russell A, Cotton E, editors. The Peto system and its evolution in Britain. London, UK: Acorn Foundation Publications; 1994.; Russell D, Rosenbaum P. Gowland C, et al. Gross Motor Function Measure (GMFM). Toronto, Canada: Gross Motor Measures Group; 1993.; Wijnhoven TM, de Onis M, Onyango AW, et al. Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food Nutr Bull. 2004;25(1 Suppl):S37–S45. doi:10.1177/15648265040251S105.; Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629–1648. doi:10.3390/toxins7051629.; Rosenbaum PL, Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288(11):1357–1363. doi:10.1001/jama.288.11.1357.; Kargo WJ, Nitz DA. Early skill learning is expressed through selection and tuning of cortically represented muscle synergies. J Neurosci. 2003;23(35):11255–11269.; Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. Curr Opin Neurobiol. 2002;12(2): 217–222. doi:10.1016/S0959-4388(02)00307-0.; Баранов А.А., Клочкова О.А., Куренков А.Л., и др. Роль пластичности головного мозга в функциональной адаптации организма при детском церебральном параличе с поражением рук // Педиатрическая фармакология. — 2012. — Т. 9. — № 6 — С. 24–32. [Baranov AA, Klochkova OA, Kurenkov AL, et al. The role ofbrain plasticity in the functional adaptation of body at cerebral infantile paralysis with the affection of hands. Pediatric pharmacology. 2012;9(6):24–32. (In Russ).] doi:10.15690/pf.v9i6.515.; Tedroff K, Lowing K, Haglund-Akerlind Y, et al. Botulinum toxin a treatment in toddlers with cerebral palsy. Acta Paediatr. 2010;99(8):1156–1162. doi:10.1111/j.1651-2227.2010. 01767.x.; Olesch CA, Greaves S, Imms C, et al. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial. Dev Med Child Neurol. 2010;52(1):79–86. doi:10.1111/j.1469-8749.2009.03387.x.; Graham HK, Boyd R, Carlin JB, et al. Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and «hips at risk»? A randomized, controlled trial. J Bone Joint Surg Am. 2008;90(1):23–33. doi:10.2106/JBJS.F.01416.; Zhu DN, Wang MM, Wang J, et al. [Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9–36 months with cerebral palsy: a prospective study. (In Chinese).] Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(2):123–129.; Pascual-Pascual SI. [Use of botulinum toxin in the preventive and palliative treatment of the hips in children with infantile cerebral palsy. (In Spanish).] Rev Neurol. 2003;37(1):80–82.; Scrutton D, Baird G, Smeeton N. Hip dysplasia in bilateral cerebral palsy: incidence and natural history in children aged 18 months to 5 years. Dev Med Child Neurol. 2001;43(9):586–600. doi:10.1017/s0012162201001086.; Pidcock FS, Fish DE, Johnson-Greene D, et al. Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. Arch Phys Med Rehabil. 2005;86(3):431–435. doi:10.1016/j.apmr.2004.03.034.; Jung NH, Heinen F, Westhoff B, et al. Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up. Neuropediatrics. 2011;42(1): 18–23. doi:10.1055/s-0031-1275344.; Chhina H, Howren A, Simmonds A, Alvarez CM. Onabotulinumtoxin A injections: a safety review of children with clubfoot under 2 years of age at BC Children’s Hospital. Eur J Paediatr Neurol. 2014;18(2):171–175. doi:10.1016/j.ejpn.2013.11.002.; Алборов О.И., Филатова Н.Б., Чочиев Г.М., и др. Ботокс в комплексной реабилитации больных с парезом Эрба // International Journal on Immunorehabilitation. — 2010. — Т. 12. — № 2 — С. 199a. [Alborov OI, Filatova NB, Chochiev GM, et al. Botoks v kompleksnoi reabilitatsii bol’nykh s parezom Erba. International Journal on Immunorehabilitation. 2010;12(2):199a. (In Russ).]; Ma J, Smith BP, Smith TL, et al. Juvenile and adult rat neuromuscular junctions: density, distribution, and morphology. Muscle Nerve. 2002;26(6):804–809. doi:10.1002/mus.10272.; Barrett RS, Lichtwark GA. Gross muscle morphology and structure in spastic cerebral palsy: a systematic review. Dev Med Child Neurol. 2010;52(9):794–804. doi:10.1111/j.1469-8749.2010.03686.x.; Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol. 1994;36(5):379–385. doi:10.1111/j.1469-8749.1994.tb11863.x.; Clowry GJ, Walker L, Davies P. The effects of botulinum neurotoxin A induced muscle paresis during a critical period upon muscle and spinal cord development in the rat. Exp Neurol. 2006;202(2): 456–469. doi:10.1016/j.expneurol.2006.07.008.; Eliasson P, Fahlgren A, Pasternak B, Aspenberg P. Unloaded rat Achilles tendons continue to grow, but lose viscoelasticity. J Appl Physiol (1985). 2007;103(2):459–463. doi:10.1152/japplphysiol.01333.2006.; Rauch F, Hamdy R. Effect of a single botulinum toxin injection on bone development in growing rabbits. J Musculoskelet Neuronal Interact. 2006;6(3):264–268.; Kwon TG, Park HS, Lee SH, et al. Influence of unilateral masseter muscle atrophy on craniofacial morphology in growing rabbits. J Oral Maxillofac Surg. 2007;65(8):1530–1537. doi:10.1016/j.joms.2006.10.059.; Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993;8(1):33–37. doi:10.1002/mds.870080106.; Gilio F, Curra A, Lorenzano C, et al. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol. 2000;48(1):20–26. doi:10.1002/1531-8249(200007) 48:13.3.co;2-l.; Boroojerdi B, Cohen LG, Hallett M. Effects of botulinum toxin on motor system excitability in patients with writer’s cramp. Neurology. 2003;61(11):1546–1550. doi:10.1212/01.wnl. 0000095965.36574; https://vsp.spr-journal.ru/jour/article/view/1729Test

الإتاحة: https://doi.org/10.15690/vsp.v16i1.1693Test
https://doi.org/10.1016/S0140-6736Test(04)16207-7
https://doi.org/10.1017/s001216220Test
https://doi.org/10.1111/j.1469-8749.2002.tb00848.xTest
https://doi.org/10.1080/09638280400018445Test
https://doi.org/10.1016/b978-1-4160-4928-9.00014-7Test
https://doi.org/10.1016/j.ejpn.2009.09.005Test
https://doi.org/10.1111/dmcn.12246Test
https://doi.org/10.1186/1471-2474-9-150Test
https://doi.org/10.1302/0301-620X.87B1.15146Test

View record in BASE

8

دورية أكاديمية

AUTOSOMAL RECESSIVE PERIPHERAL NEUROPATHY WITH NEUROMYOTONIA (ARAN-NM): DESCRIPTION OF A CLINICAL CASE CONFIRMED BY A MUTATION IN THE HINT1 GENE ; АУТОСОМНО-РЕЦЕССИВНАЯ ПЕРИФЕРИЧЕСКАЯ НЕЙРОПАТИЯ С НЕЙРОМИОТОНИЕЙ (ARAN-NM): ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ, ПОДТВЕРЖДЕННОГО МУТАЦИЕЙ В ГЕНЕ HINT1

المؤلفون: Olga A. Klochkova, Alexey L. Kurenkov, Natalya V. Zhurkova, Kirill V. Savostyanov, Ilya S. Zhanin, Ayaz M. Mamedyarov, Ilona M. Tardova, О. А. Клочкова, А. Л. Куренков, Н. В. Журкова, К. В. Савостьянов, И. С. Жанин, А. М. Мамедьяров, И. М. Тардова

المساهمون: 10.15690/vsp.v16i4.1780

المصدر: Current Pediatrics; Том 16, № 4 (2017); 326-333 ; Вопросы современной педиатрии; Том 16, № 4 (2017); 326-333 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: болезнь Шарко–Мари–Тутса 2-го типа, HINT1 gene, ARAN-NM, neuromyotonia, peripheral neuropathy with neuromyotonia, hereditary polyneuropathy, motor neuropathy, Charcot–Marie–Tooth disease type 2, ген HINT1, нейромиотония, периферическая нейропатия с нейромиотонией, наследственная полинейропатия, моторная нейропатия

وصف الملف: application/pdf

العلاقة: https://vsp.spr-journal.ru/jour/article/view/1793/719Test; Говбах И.А. Современные подходы диагностики наследственных мото-сенсорных нейропатий // ScienceRise. — 2015. — Т. 3. — № 4 — С. 43–53. [Govbakh IA. Modern approaches to diagnostics of hereditary motor-sensory neuropathy. ScienceRise. 2015;3(4)43–53. (In Russ).] doi:10.15587/2313-8416.2015.39134; Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(1):1–14. doi:10.1111/j.1529-8027.2011.00324.x.; Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22–33. doi:10.1002/ana.22166.; Lassuthova P, Brozkova DS, Krutova M, et al. Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy among Czech patients and neuromyotonia is rather an underdiagnosed symptom. Neurogenetics. 2015;16(1):43–54. doi:10.1007/s10048-014-0427-8.; Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009; 8(7):654–667. doi:10.1016/S1474-4422(09)70110-3; Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry. 2009;80(12): 1304–1314. doi:10.1136/jnnp.2008.158295.; Zhao H, Race V, Matthijs G, et al. Exome sequencing reveals HINT1 mutations as a cause of distal hereditary motor neuropathy. Eur J Hum Genet. 2014;22(6):847–850. doi:10.1038/ejhg.2013.231.; Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatry. 2012;83(1):6–14. doi:10.1136/jnnp-2011-300952.; Zimon M, Baets J, Almeida-Souza L, et al. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet. 2012;44(10):1080–1083. doi:10.1038/ng.2406.; Aminkeng F. HINT1 mutations define a novel disease entity — autosomal recessive axonal neuropathy with neuromyotonia. Clin Genet. 2013;83(1):31–32. doi:10.1111/cge.12030.; Mertens HG, Zschocke S. [Neuromyotonia. (In German).] Klin Wochenschr. 1965;43(17):917–925. doi:10.1007/BF01712058; Lance JW, Durke D, Pollard J. Neuromyotonia in the spinal form of Charcot-Marie-Tooth disease. Clin Exp Neurol. 1979;16:49–56.; Peeters K, Chamova T, Tournev I, Jordanova A. Axonal neuropathy with neuromyotonia: there is a HINT. Brain. 2017;140:868–877. doi:10.1093/brain/aww301.; Hahn AF, Parkes AW, Bolton CF, Stewart SA. Neuromyotonia in hereditary motor neuropathy. J Neurol Neurosurg Psychiatry. 1991;54(3):230–235. doi:10.1136/jnnp.54.3.230.; Black JT, Garcia-Mullin R, Good E, Brown S. Muscle rigidity in a newborn due to continuous peripheral nerve hyperactivity. Arch Neurol. 1972;27(5):413–425. doi:10.1001/archneur.1972.00490170045007; Auger RG, Daube JR, Gomez MR, Lambert EH. Hereditary form of sustained muscle activity of peripheral nerve origin causing generalized myokymia and muscle stiffness. Ann Neurol. 1984;15(1): 13–21. doi:10.1002/ana.410150104.; Mcguire SA, Tomasovic JJ, Ackerman N. Hereditary Continuous Muscle-Fiber Activity. Arch Neurol. 1984;41(4):395–396. doi:10.1001/archneur.1984.04050160057016; Grund G. [Zur Frage des Vorkommens erworbener Myotonie. (In German).] Dtsch Z Nervenheilkd. 1911;42(1–2):110–127. doi:10.1007/bf01649723.; Grund G. [Uber genetische Beziehungen zwischen Myotonie, Muskelkrampfen und Myokymie. (In German).] Dtsch Z Nervenheilkd. 1938;146(1–2):3–14. doi:10.1007/bf01762426.; Gamstorp I, Wohlfart G. A syndrome characterized by myokymia, myotonia, muscular wasting and increased perspiration. Acta Psychiatr Scand. 1959;34(2):181–194. doi:10.1111/j.1600-0447.1959.tb07573.x.; Vasilescu C, Alexianu M, Dan A. Neuronal type of Charcot-Marie-Tooth Disease with a syndrome of contrinuous motor unit activity. J Neurol Sci. 1984;63(1):11–25. doi:10.1016/0022-510x(84)90105-9.; Zimon M, Battaloglu E, Parman Y, et al. Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth neuropathies using a homozygosity mapping approach. Neurogenetics. 2014;16(1):33–42. doi:10.1007/s10048-014-0422-0.; Мальмберг С.А., Куренков А.Л. Аксональная моторная полиневропатия с гиперактивностью двигательных единиц // Неврологический журнал. — 2002. — Т. 7. — № 6 — С. 28–33. [Mal’mberg SA, Kurenkov AL. Aksonal’naya motornaya polinevropatiya s giperaktivnost’yu dvigatel’nykh edinits. Journal of neurology. 2002;7(6):28–33. (In Russ).]; Никитин С.С., Куренков А.Л. Методические основы транскраниальной магнитной стимуляции в неврологии и психиатрии. — М.: «ИПЦ Маска»; 2006. — С. 160–166. [Nikitin SS, Kurenkov AL. Metodicheskie osnovy transkranial’noi magnitnoi stimulyatsii v nevrologii i psikhiatrii. Moscow: Maska; 2006. p. 160–166. (In Russ).]; Barbier E, Zapata A, Oh E, et al. Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. Neuropsychopharmacology. 2007;32(8):1774–1782. doi:10.1038/sj.npp.1301301.; Liu Q, Puche AC, Wang JB. Distribution and expression of protein kinase c interactive protein (PKCI/HINT1) in mouse central nervous system (CNS). Neurochem Res. 2008;33(7):1263–1276. doi:10.1007/s11064-007-9578-4.; Caetano JS, Costa C, Baets J, et al. Autosomal recessive axonal neuropathy with neuromyotonia: a rare entity. Pediatr Neurol. 2014;50(1):104–107. doi:10.1016/j.pediatrneurol. 2013.08.028.; Jerath NU, Shy ME, Grider T, Gutmann L. A case of neuromyotonia and axonal motor neuropathy: a report of a HINT1 mutation in the United States. Muscle Nerve. 2015;52(6):1110-1113. doi:10.1002/mus.24774.; Rauchenzauner M, Fruhwirth M, Hecht M, et al. A novel variant in the HINT1 gene in a girl with autosomal recessive axonal neuropathy with neuromyotonia: thorough neurological examination gives the clue. Neuropediatrics. 2016;47(2):119–122. doi:10.1055/s-0035-1570493.; Boaretto F, Cacciavillani M, Mostacciuolo ML, et al. Novel loss-of-function mutation of the HINT1 gene in a patient with distal motor axonal neuropathy without neuromyotonia. Muscle Nerve. 2015;52(4):688–689. doi:10.1002/mus.24720.; Вавилов М.А., Бландинский В.Ф., Громов И.В. и др. Артродезирующие операции у детей старше 10 лет с деформациями стоп различной этиологии // Гений ортопедии. — 2016. — № 3 — С. 35–38. [Vavilov MA, Blandinskii VF, Gromov IV, et al. Arthrodesing surgeries in children above 10 years of age with feet deformities of various etiologies. Genij ortopedii. 2016;(3):35–38. (In Russ).] doi:10.18019/1028-4427-2016-3-35-38.; https://vsp.spr-journal.ru/jour/article/view/1793Test

الإتاحة: https://doi.org/10.15690/vsp.v16i4.1780Test
https://doi.org/10.15587/2313-8416.2015.39134Test
https://doi.org/10.1111/j.1529-8027.2011.00324.xTest
https://doi.org/10.1002/ana.22166Test
https://doi.org/10.1007/s10048-014-0427-8Test
https://doi.org/10.1016/S1474-4422Test(09)70110-3
https://doi.org/10.1136/jnnp.2008.158295Test
https://doi.org/10.1038/ejhg.2013.231Test
https://doi.org/10.1136/jnnp-2011-300952Test
https://doi.org/10.1038/ng.2406Test

View record in BASE

9

دورية أكاديمية

Multilevel Botulinum Toxin A (Abobotulinum Toxin A) Injections in Spastic Forms of Cerebral Palsy: Retrospective Analysis of 8 Russian Centers Experience ; Многоуровневые инъекции ботулинического токсина типа А (Абоботулотоксина) при лечении спастических форм детского церебрального паралича: ретроспективное исследование опыта 8 российских центров

المؤلفون: O. A. Klochkova, A. L. Kurenkov, K. M. Karimova, B. I. Bursagova, L. S. Namazova-Baranova, A. M. Mamedyarov, L. M. Kuzenkova, I. M. Tardova, I. V. Fal’kovskiy, O. G. Dontzov, M. A. Ryzhenkov, V. A. Zmanovskaya, M. N. Butorina, O. L. Pavlova, N. N. Harlamova, D. M. Dankov, E. V. Levitina, D. A. Popkov, S. O. Ryabykh, S. N. Medvedeva, E. B. Gubina, L. N. Vladykina, V. M. Kenis, T. I. Kiseleva, D. A. Krasavina, O. N. Vasil’eva, A. S. Nosko, V. P. Zykov, V. I. Michnovich, T. A. Belogorova, L. V. Rychkova, О. А. Клочкова, А. Л. Куренков, Х. М. Каримова, Б. И. Бурсагова, Л. С. Намазова-Баранова, А. М. Мамедьяров, Л. М. Кузенкова, И. М. Тардова, И. В. Фальковский, О. Г. Донцов, М. А. Рыженков, В. А. Змановская, М. Н. Буторина, О. Л. Павлова, Н. Н. Харламова, Д. М. Данков, Е. В. Левитина, Д. А. Попков, С. О. Рябых, С. Н. Медведева, Е. Б. Губина, Л. Н. Владыкина, В. М. Кенис, Т. И. Киселёва, Д. А. Красавина, О. Н. Васильева, А. С. Носко, В. П. Зыков, В. И. Михнович, Т. А. Белогорова, Л. В. Рычкова

المصدر: Pediatric pharmacology; Том 13, № 3 (2016); 259-269 ; Педиатрическая фармакология; Том 13, № 3 (2016); 259-269 ; 2500-3089 ; 1727-5776

مصطلحات موضوعية: многоуровневая ботулинотерапия, spasticity, botulinum toxin A, Abobotulinum toxin A, multilevel injections, спастичность, ботулинический токсин типа А, абоботулотоксин

وصف الملف: application/pdf

العلاقة: https://www.pedpharma.ru/jour/article/view/1425/798Test; Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1): 45–66. doi:10.1016/j.ejpn.2009.09.005.; Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg [Am]. 2006;88(1):161–170. doi:10.2106/jbjs.c.01497.; Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910. doi:10.1111/ dmcn.12246.; Кенис В.М. Эффективность использования препаратов бутолотоксина при коррекции динамической эквинусной и эквиноварусной деформации стопы у детей с гемипаретической формой церебрального паралича // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2012. — Т. 112. — №7–2. —С. 29–33. [Kenis VM. Efficacy of botulinum toxin in the treatment of dynamic equinus and equinovarus foot deformities in children with hemiplegic cerebral palsy. Zh Nevrol Psikhiatr Im SS Korsakova. 2012;112(7–2):29–33. (In Russ).]; Simpson DM, Gracies JM, Graham HK, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–1698. doi:10.1212/ 01.wnl.0000311391.00944.c4.; Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and; the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–343. doi:10.1212/wnl.0b013e3181cbcd2f.; Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy – a short review of different injection techniques. Neurotox Res. 2006;9(2– 3):189–96. Review. doi:10.1007/bf03033938.; Molenaers G, Van Campenhout A, Fagard K, et al. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop. 2010;4(3):183–195. doi:10.1007/ s11832-010-0246-x.; Куренков А.Л., Клочкова О.А., Каримова Х.М., и др. Выбор дозы препарата ботулинического токсина типа А при лечении спастических форм детского церебрального паралича // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2015. — Т. 115. — №5–2. — С. 35—41. [Kurenkov AL, Klochkova OA, Karimova KhM, et al. Selection of a dose of the botulinum toxin A in spastic forms of cerebral palsy. Zh Nevrol Psikhiatr Im SS Korsakova. 2015;115(5–2):35–41. (In Russ).]; Клочкова О.А., Куренков А.Л., Каримова Х.М., и др. Опыт многоуровневых повторных инъекций ботулинического токсина типа А (Abobotulinum toxin A) при спастических формах детского церебрального паралича // Вестник РАМН. — 2014. — Т. 69. — №9–10. — С. 57—63. [Klochkova OA, Kurenkov AL, Karimova KM,et al. Clinical experience of the repeated multilevel injections of the botulinum toxin type A (abobotulinum toxin A) in the spastic forms of Cerebral palsy. Vestn Ross Akad Med Nauk. 2014;69(9–10):57– 63. (In Russ).] doi:10.15690/vramn.v69i9-10.1132.; Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629–1648. doi:10.3390/toxins7051629.; Куренков А.Л., Клочкова О.А., Бурсагова Б.И., и др. При менение препарата ботулинического токсина типа А (Ботокс) в лечении детского церебрального паралича // Нервно-мышечные болезни. — 2014. — №3. — С. 28—41. [Kurenkov AL, Klochkova OA, Bursagova BI, et al. Use of botulinum toxin type A (Botox) in the treatment of infantile cerebral palsy. Nervnomyshechnye bolezni. 2014;(3):28–41. (In Russ).]; Sakzewski L, Ziviani J, Boyd R. Systematic review and metaanalysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics. 2009;123(6): 1111–1122. doi:10.1542/peds.2008-3335.; Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214–223. doi:10.1111/j.1469-8749.1997.tb07414.x.; Баранов А.А., Намазова-Баранова Л.С., Куренков А.Л., и др. Комплексная оценка двигательных функций у пациентов с детским церебральным параличом. Учебно- методическое пособие. Федеральное государственное бюджетное научное учреждение «Научный центр здоровья детей». — М.: ПедиатрЪ; 2014. 84 с. [Baranov AA, Namazova-Baranova LS, Kurenkov AL, et al. Kompleksnaya otsenka dvigatel’nykh funktsii u patsientov s detskim tserebral’nym paralichom. Uchebno-metodicheskoe posobie.; Federal’noe gosudarstvennoe byudzhetnoe nauchnoe uchrezhdenie «Nauchnyi tsentr zdorov’ya detei». Moscow: Pediatr, 2014. 84 p. (In Russ).]; Fehlings D, Novak I, Berweck S, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hyperto - nicity: international consensus statement. Eur J Neurol. 2010;17 (Suppl. 2):38-56. doi:10.1111/j.1468-1331.2010.03127.x.; Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after- care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17(Suppl. 2):9-37. doi:10.1111/j.1468-1331.2010.03126.x.; Hoare BJ, Wallen MA, Imms C, et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. 2010;(1):CD003469. doi:10.1002/14651858.cd003469.pub4.; Berweck S, Kirschner J, Heinen F. Therapy with botulinum toxin. In: Paediatric Neurology. Theory and practice. Panteliadis CP, Korinthenberg R, editors. Stuttgart, New York: Thieme; 2005. P. 925–951.; Bakheit AM. Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centers. Eur J Neurol. 2003;10(4):415-419. doi:10.1046/j.1468- 1331.2003.00619.x.; Pascual Pascual SI. Paralisis cerebral infantil: aspestos clinicos, clasificaciones y tratamientos. Madrid: EDICIONES MAYO, S.A.; 2012. 28 p.; Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebocontrolled study. Dev Med Child Neurol. 2006;48(1):10-13. doi:10.1017/s0012162206000041.; rosminzdrav.ru [интернет]. Инструкция по медицинскому применению лекарственного препарата Диспорт [доступ от 13.06.2016]. Доступ по ссылке http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=27864&tTest=; https://www.pedpharma.ru/jour/article/view/1425Test

الإتاحة: https://doi.org/10.15690/pf.v13i3.1576Test
https://doi.org/10.1016/j.ejpn.2009.09.005Test
https://doi.org/10.2106/jbjs.c.01497Test
https://doi.org/10.1212/wnl.0b013e3181cbcd2fTest
https://doi.org/10.1007/bf03033938Test
https://doi.org/10.15690/vramn.v69i9-10.1132Test
https://doi.org/10.3390/toxins7051629Test
https://doi.org/10.1542/peds.2008-3335Test
https://doi.org/10.1111/j.1469-8749.1997.tb07414.xTest
https://doi.org/10.1111/j.1468-1331.2010.03127.xTest

View record in BASE

10

دورية أكاديمية

Aromaphytobalneotherapy in Treatment and Prophylaxis of Frequent Respiratory Infections in Children with Chronic and Disabling Diseases

المؤلفون: O. M. Konova, E. G. Dmitrienko, T. G. Dmitrienko, E. V. Sakharova, A. M. Mamedyarov, N. I. Taybulatov

المصدر: Pediatričeskaâ Farmakologiâ, Vol 13, Iss 5, Pp 482-487 (2016)

مصطلحات موضوعية: aromatherapy, balneotherapy, children, chronic diseases, frequent respiratory infections, Therapeutics. Pharmacology, RM1-950

العلاقة: https://www.pedpharma.ru/jour/article/view/1467Test; https://doaj.org/toc/1727-5776Test; https://doaj.org/toc/2500-3089Test; https://doaj.org/article/dcbd1942a0a64b5593a812886ba438ddTest

الإتاحة: https://doi.org/10.15690/pf.v13i5.1644Test
https://doaj.org/article/dcbd1942a0a64b5593a812886ba438ddTest

View record in BASE

تنقيح النتائج